SIRTURO® Is the First Medication for Pulmonary MDR-TB With a Novel Mechanism of Action in Over 40 Years

Mechanism of Action

  • SIRTURO® is the first anti-TB drug to interfere with bacterial energy metabolism.
    • SIRTURO® specifically inhibits mycobacterial ATP (adenosine 5'-triphosphate) synthase, by binding to subunit c of the enzyme that is essential for the generation of energy in Mycobacterium tuberculosis.

Download a comprehensive resource on SIRTURO® (bedaquiline) tablets




Janssen Therapeutics, Division of Janssen Products, LP

This site is published by Janssen Therapeutics, Division of Janssen Products, LP, which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Therapeutics, Division of Janssen Products, LP, recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Last updated November 2, 2022

cp-37624v6